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Besides the classical prognostic factors used in clinical practice, a
series of biological markers have been tested for their predictive
value regarding survival or treatment responses in breast cancer
(Figueroa et al, 1993; Porter-Jordan and Lippman, 1994). Most
interpretations of the data have been complicated by the use of
different techniques for measurement and analysis, but such new
parameters could be of interest in selecting high-risk groups,
especially among node-negative patients. Among the plethora of
potentially useful markers that have been identified, two appear to
be of particular interest: urokinase-type plasminogen activator
(uPA) and p53. UPA has a role in the destruction of the basement
membrane and in invasion (Andreasen et al, 1997), and several
studies from different countries indicate that uPA overexpression,
measured by biochemical methods, is strongly related to shorter
disease-free and overall survival, particularly in node-negative
patients (Duffy, 1996). These results led a German group to initiate
a clinical trial in node-negative patients (Jänicke et al, 1994b).
Mutations of the tumour suppressor gene p53 are the most
frequent known genetic alterations in all human cancers. Most
biologically significant mutations hinder the participation of
p53 in maintaining genomic stability (Gottlieb and Oren, 1996).
p53 gene alterations and accumulation of p53 protein detected
mainly by immunohistochemistry are generally related to shorter
disease-free survival (Velculescu and El-Deiry, 1996). Mis-sense
mutations normally result in an increased half-life of the protein
product and accumulation of mutant p53 protein in the nucleus.
Methodological differences and variability in immunohisto-
chemical assays may explain discordant results regarding the
prognostic significance of p53 accumulation in breast cancer
(Allred et al, 1993; Thor and Yandell, 1993).
In this study we tested an automatic quantitative assay for uPA
and p53 protein accumulation, and evaluated the prognostic value
of these markers in a multicentre study. The study included 1245
tumours from primary breast cancer patients from seven French
institutions. Patients were followed for a median of 75 months.
Measurements were made using an automatic quantitative
biochemical method (Borg et al, 1995; De Witte et al, 1996; Fernö
et al, 1996; Berns et al, 1997; Bouchet et al, 1998; Peyrat et al,
1998), which is feasible for routine determination on cytosols
prepared for hormone receptor assays.
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Summary The purpose of this retrospective multicentre study was to assess the prognostic value of urokinase plasminogen activator (uPA)
and p53 levels in a large series of primary breast cancer, using an automatic quantitative luminometric method. Samples of 1245 operable
breast tumours were collected from seven French institutions and patients were followed for a median of 75 months. The median uPA and p53
levels assayed in cytosols by means of the immunoluminometric technique (LIA) were 0.31 and 0.20 ng mg–1 of protein respectively. In
univariate analysis, high levels of uPA and p53 were associated with shorter disease-specific survival, disease-free interval, and distant
recurrence-free interval. The 5-year survival rates were 95.5% among patients with uPA values below the 20th percentile, and 77.5% in those
with values above the 80th percentile. The 5-year survival rates were 91.0% in patients with p53 values below the 20th percentile, and 77.6%
in those with values above the 80th percentile. In multivariate analysis, the risk of disease-related death increased with uPA levels after
adjustment for tumour size, histological grade, lymph node involvement, and estrogen receptor status. A high level of uPA was also related to
a shorter disease-free interval and distant recurrence-free interval. In node-negative patients, a high level of uPA remained strongly related to
the three outcomes. When adjusted for other prognostic factors, p53 was no longer significantly related to the outcomes. Given its rapidity and
simple application to routinely prepared cytosols, this LIA may be useful for evaluating the prognostic impact of uPA in primary breast cancer,
particularly in node-negative patients. According to our results, the prognostic value of p53 accumulation is limited when uPA is included in
multivariate analysis.
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MATERIALS AND METHODS
Patients’ characteristics
This study involved 1245 patients diagnosed and treated at seven
cancer centres between the beginning of 1980 and the end of 1994.
The patients presented with unilateral non-metastatic breast
tumours and were initially treated with modified mastectomy or
breast-conserving surgery. The following information was
recorded for each patient: age at diagnosis, hormone status,
clinical stage, histological classification and grade, pathological
tumour size, axillary lymph node involvement, steroid receptor
status, uPA and p53 values, and primary treatment.
The median age was 58 years (range 24–88). A total of 223
patients (18%) were under 45 years of age, 670 (54%) were
between 46 and 65 years, and 352 (28%) were over 65 (Table 1).
Menopausal status was defined as 2 years after complete
arrest of periods
Sixty-six per cent of the patients were post-menopausal.
Significant differences (P < 0.001) in mean age was observed
between the centres. According to UICC criteria (UICC, 1988), 13
(1%) patients had stage 0 disease, 239 (19%) stage I, 884 (72%)
stage II and 99 (8%) stage III. The median pathologic tumour size
was 22 mm (0–150). Most of the patients (89%) had invasive
ductal carcinoma and 8% had lobular carcinoma; the other histo-
logical types were analysed as a group (3%). A total of 1141
tumours were graded according to the Scarff Bloom and
Richardson (SBR) classification (Bloom and Richardson, 1957;
Scarff and Torloni, 1968) (SBR I 16%, SBR II 58%, SBR III
26%). Axillary lymph node status (mean number examined 14)
was assessed by histological examination in 1141 cases. Six
hundred and sixteen patients (54%) were node-negative, 319
(28%) had one to three invaded nodes, and 206 (18%) had more
than four invaded nodes. Significant differences in median tumour
size, clinical stage, the proportion of positive or negative lymph
nodes and histological grade were observed among the centres
(P < 0.0001). The primary treatment was tumorectomy (63.5%) or
mastectomy with axillary dissection (36.5%). Of the entire popula-
tion, 84% had radiotherapy following surgery. Nineteen per cent of
the patients received chemotherapy, 25% received hormone
therapy and 14% received both.
Tissue extracts
Tumour tissue was collected from 1245 patients treated in six
French cancer centres and in the Assistance Publique of Marseille.
Oestrogen (ER) and progesterone (PR) receptor assays
A section of tumour tissue was frozen in liquid nitrogen immedi-
ately after surgery. The hormone receptor status of the tumour was
recorded at the time of surgery. The tumour was considered
to be steroid receptor-positive if ER and PR values exceeded
10 fmol mg–1 cytosol protein. Quality control was based on regular
testing of both internal controls (pooled cytosols) and European
Organization for Research and Treatment of Cancer (EORTC,
1980) controls. Approximately two-thirds of the tumours were
positive (ER = 73%, PR = 64%). Significant differences in the
proportions of ER and PR positivity were observed among the
different centres (P < 0.0001).
For uPA and p53 assays, four laboratories (laboratories 2, 4 and
5 in Table 2) used cytosols prepared for hormone receptor assays
at the time of initial surgery and then frozen in liquid nitrogen. The
other three laboratories prepared cytosols specifically for this
study by homogenizing fragments of frozen tumours in the same
hormone receptor buffer (10 mM Tris-HCl, pH =7.4, 1.5 mM
EDTA, 10 mM Na2MoO4, 0.5 mM dithiotreitol, 10% glycerol).
After centrifugation for 1 h at 105 000 g, supernatants were
aliquoted and stored in liquid nitrogen until analysis (maximum 3
months). uPA and p53 assays were performed in each centre with
the same methodology. Internal controls (pooled cytosols) were
used for each parameter in each series of tests. Cytosol extract
protein concentrations were determined using the BCA assay
(Pierce, Rockford, IL, USA). All assays were done in duplicate.
Luminometric immunoassay for p53 and uPA
p53 (n = 1231) and uPA (n = 1094) were assayed by using a
luminometric immunoassay (LIA-mat p53 and LIA-mat uPA, Byk
Table 1 Population characteristics
Characteristics Number of patients (%)
Age
Mean (years) 58
Range (min, max) 24–88
≤ 45 223 (18)
46–65 670 (54)
> 65 352 (28)
Hormonal status
Premenopausal 414 (34)
Post-menopausal 813 (66)
ND 18
UICC stage
0 13 (1)
I 239 (19)
II 884 (72)
III 99 (8)
ND 10
Pathological tumour size (pT)
≤ 20 mm 428 (35)
21–50 mm 731 (60)
> 50 mm 55 (5)
ND 31
Histology
Ductal 1105 (89)
Lobular 105 (8)
Other histology 35 (3)
Histological grading (SBR)
I 180 (16)
II 660 (58)
III 301 (26)
ND 104
Axillary lymph nodes (pN)
None 616 (54)
1–3 319 (28)
³ 4 206 (18)
ND 104
ER status
Negative 333 (27)
Positive 905 (73)
ND 7
PR status
Negative 447 (36)
Positive 790 (64)
ND 8
ND: not determined, ER: estrogen receptor, PR: Progesterone receptor.538 P Broët et al
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Sangtec Diagnostica, Bromma, Sweden) based on a monoclonal
antibody (mAb) two-site single-incubation procedure according
to the manufacturer’s instructions. Antibody-coated polystyrene
tubes serve as the solid phase. For p53, the tubes are coated with
Pab 1801 mAb and the isoluminol derivative is conjugated to the
mAb DO1. Both mAbs bind to denaturation-resistant epitopes at
the N-terminus of the wild-type and mutant p53 protein (Banks
et al, 1986; Vojtesek et al, 1992). In the case of uPA, the mAb
detects the protein in proenzyme form, the active two-chain uPA,
uPA bound to its receptor, and uPA bound to plasminogen
activator inhibitor type 1 (PAI-1). The uPA and p53 assay pro-
cedures have been described elsewhere (Borg et al, 1995; Fernö
et al, 1996). The sensitivity of the LIA was < 0.010 ng ml–1 for p53
and < 0.005 ng ml–1 for uPA.
Statistical methods
Comparison between uPA and p53 levels and clinical and histo-
logical features were performed by using non-parametric tests. We
used the Spearman rank correlation when variables were con-
tinuous and the Kruskall–Wallis tests for categorized variables.
Two-sided  P-values below 0.05 were considered significant.
Disease-related deaths were scored as events with censoring of the
other patients for death due to causes other than disease progres-
sion, at the time of last follow-up. Primary failure was defined as
the occurrence of a loco-regional and/or distant recurrence. Local
recurrence was defined as a tumour arising in the treated breast or
as a nodal recurrence. Primary failures were scored as an event,
censoring the other patients at the time of the last follow-up or
death. Disease-specific survival, disease-free interval and distant
recurrence-free interval were calculated from the date of first treat-
ment. Disease-specific survival was the time interval between the
date of first treatment and the date of disease-related death.
Disease-free interval and distant recurrence-free interval were the
time intervals between the date of first treatment and the date of
primary failure or distant recurrence respectively. Survival curves
were derived from Kaplan–Meier (Kaplan and Meier, 1958)
estimates, and survival rates are presented with their standard
deviation. The problem of using the so-called ‘optimal’ cut-points,
which could overestimate the effect of uPA and p53, led us to use
pre-specified cut-points when examining the functional relation-
ship between these markers and outcome (Altman, 1991; Altman
et al, 1994). We considered four prespecified cut-points corre-
sponding to the 20th, 40th, 60th and 80th percentiles in the overall
population. In univariate analysis, the influence of uPA and p53
was determined by using the log-rank test (Mantel, 1966). The
influence of uPA and p53 on outcome, adjusted for the other
prognostic factors, was assessed in multivariate analyses by using
the Cox proportional hazards regression model (Cox, 1972) in a
forward step-wise procedure. To take account of differences
among centres, we stratified the multivariate analyses according to
the centre.
As the true relationship between the markers and outcomes
could be smooth rather than discontinuous, we compared the fit of
the model for the two markers as categorized variables (dummy
variables) and continuous variables (with a linear function). In this
latter case, considering that the distributions of uPA and p53 are
highly positively skewed, the markers were log transformed and
compared by using Aikaike’s criterion, which gives the best-fit
model as that with the minimum Akaike information criterion
(Akaike, 1974), allowing comparisons between non-nested
models. To investigate whether uPA and p53 are important prog-
nostic factors in node-negative breast carcinoma, we applied a
Cox model to this low-risk subgroup. Confounding variables with
k subgroups were coded to k-1 dummy variables, yielding a non-
linear relation between two subsequent subgroups when k > 2. To
reveal a time-varying effect of uPA and p53, we tested for a non-
proportional effect based on the Schoenfeld residuals (Therneau
et al, 1990). Interactions between the prognostic value of uPA and
p53 and therapeutic factors were also tested in the Cox model. All
these analyses were performed with the S-Plus software package
(S-Plus, 1993).
RESULTS
uPA and p53
The median uPA level in the 1094 tumours analysed was
0.31 ng mg–1 protein (mean 0.46, percentiles 0.13, 0.24, 0.39 and
0.72). The median p53 level in the 1231 tumours analysed was
0.20 ng mg–1 protein (mean 1.44, percentiles 0.05, 0.14, 0.27 and
0.54). Table 2 summarizes uPA and p53 values in each partici-
pating centre and Table 3 gives the correlations with clinical and
histological characteristics. Higher levels of uPA were related to
older age, larger tumour size, higher clinical stage, higher
Table 2 uPA and p53 according to the participating centres
Centre uPA p53
n Median Mean 20–80th n Median Mean 20–80th
ng mg–1 ng mg–1 percentile ng mg–1 ng mg–1 percentile
proteins proteins proteins proteins
1 499 0.38 0.53 0.16–0.85 499 0.19 1.35 0.05–0.52
2 222 0.21 0.30 0.10–0.47 223 0.21 0.79 0.02–0.48
3 161 0.45 0.64 0.17–0.94 161 0.15 2.85 0.05–0.48
4 119 0.22 0.28 0.08–0.43 109 0.25 1.34 0.09–0.56
5 93 0.24 0.31 0.11–0.42 93 0.20 1.05 0–0.7
6 – ND ND ND 92 0.36 1.75 0.13–0.78
7 – ND ND ND 54 0.18 1.05 0.09–0.42
Total 1094 0.31 0.46 0.13–0.72 1231 0.20 1.44 0.05–0.54
ND: not determined, n: number, uPA: urokinase-type plasminogen activator, p53: p53 protein.Quantitative biochemical assays of uPA and p53 in 1245 primary breast cancer patients 539
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histological grade, ductal histology and ER negativity. Higher
levels of p53 were related to older age, larger tumour size, higher
histological and clinical grade, and ductal histology. Levels of
uPA correlated positively with p53 levels (r = 0.27, P < 0.0001).
Patient outcome
The median follow-up was 75 months (range 3–197). At the time
of the analysis, 109 local-regional recurrences, 281 metastases and
235 deaths (223 disease-related) had been recorded. Disease-
specific survival was 86% (±1.0) at 60 months and 76% (±1.2) at
96 months. Primary failure had not occurred in 80% (±1.1) of the
patients at 60 months and 64% (±1.5) at 96 months. A total of 80%
(±1.1) of the patients were distant recurrence-free at 60 months,
compared to 71% (±1.5) at 96 months.
Univariate analysis
The probabilities of disease-specific survival, disease-free interval
and distant recurrence-free interval for the four percentiles are
illustrated in Figure 1 for uPA and Figure 2 for p53. High levels of
uPA and p53 were significantly associated with shorter disease-
specific survival, disease-free interval and distant recurrence-free
interval.
The 5-year disease-specific survival rates were 95.5% (± 1.5) in
patients with uPA values below the 20th percentile, and 77.5%
(± 3.0) in those with values above the 80th percentile (Table 4).
The 5-year disease-specific survival rate was 91.0% (± 1.9) among
patients with p53 values below the 20th percentile, and 77.6%
(± 2.8) in those with values above the 80th percentile.
At five years, 85.6% (± 2.5) of patients with uPA values below
the 20th percentile, and 63.6% (± 3.4) of those with values above
the 80th percentile were free from disease recurrence. At five
years, 82.8% (± 2.4) of patients with p53 values below the 20th
percentile, and 67.5% (± 3.2) of those with values above the 80th
percentile were free of disease recurrence.
At five years, 88.0% (± 2.3) of patients with uPA values below
the 20th percentile and 68.5% (± 3.3) of those with values above
the 80th percentile were free of distant recurrence. At five years,
86.4% (± 2.2) of patients with p53 values below the 20th
percentile and 71.3% (± 3.1) of those with values above the 80th
percentile were free of distant recurrence.
Multivariate analysis – overall population
Besides p53 and uPA, the following variables were assessed in
multivariate analysis: age at first treatment, menopausal status,
clinical stage, lymph node involvement, histoprognostic grading
and steroid receptor status. Table 5 shows the results of the final
Cox models. The risk of disease-related death increased with posi-
tive lymph nodes, high uPA levels, SBR III histological grade,
ER-negative tumours and a tumour size larger than 20 mm. The
disease-free interval was shorter in case of high uPA levels, more
than three invaded lymph nodes, SBR II and III histological grade,
tumour larger than 20 mm and ER-negative tumours. The risk
of developing distant recurrence increased with more than
three invaded lymph nodes, high uPA levels, tumour size larger
than 20 mm, SBR II and III histological grade, and ER-negative
tumours.
For these three outcomes, p53 status (categorized or contin-
uous) was not an independent prognostic factor, whether or not
uPA was included in the model (not shown here). According to the
Akaike criterion, the best fit was obtained when uPA was included
Table 3 Correlation between uPA, p53 and clinical or histological
characteristics
Patient uPA p53
Median P-value Median P-value
Age (years)
≤ 45 0.30 0.2
46–65 0.30 0.05 0.18 0.01
>65 0.35 0.24
Hormonal status
Premenopausal 0.31 0.19
Post-menopausal 0.31 0.89 0.20 0.12
UICC stage
0–I 0.25 0.15
II 0.32 0.0001 0.21 0.0007
III–IV 0.45 0.21
Pathological tumour
size (pT)
≤ 20 mm 0.28 0.16
21–50 mm 0.34 0.0005 0.21 0.0001
>50 mm 0.42 0.24
Histology
Ductal and other 0.34 0.21
Lobular 0.13 0.0001 0.10 0.0001
Histological grading
(SBR)
I 0.28 0.12
II 0.31 0.0001 0.20 0.0001
III 0.45 0.28
Axillary lymph node
(pN)
None 0.32 0.19
1–3 0.32 0.33 0.21 0.73
³4 0.33 0.20
ER status
Negative 0.41 0.18
Positive 0.29 0.0001 0.20 0.14
PR status
Negative 0.33 0.18
Positive 0.30 0.07 0.20 0.36
ER: Estrogen receptor, PR: progesterone receptor.
Table 4 Five years results according to uPA and p53
Disease-specific Disease-free Distant
survival (%) interval (%) recurrence-free
interval (%)
5 years (s.d.) 5 years (s.d.) 5 years (s.d.)
uPAa
<0.13 95.5 (1.5) 85.6 (2.5) 88.0 (2.3)
0.13, 0.24 88.5 (2.2) 78.9 (2.8) 83.3 (2.6)
0.24, 0.39 85.6 (2.5) 75.8 (3.0) 79.9 (2.8)
0.39, 0.72 84.6 (2.5) 74.5 (2.5) 77.8 (2.9)
>0.72 77.5 (3.0) 63.6 (3.4) 68.5 (3.3)
P < 0.00001 P < 0.00001 P < 0.00001
p53a
<0.05 91.0 (1.9) 82.8 (2.4) 86.4 (2.2)
0.05, 0.14 86.1 (2.4) 79.3 (2.7) 81.9 (2.6)
0.14, 0.27 87.0 (2.3) 75.5 (2.9) 80.9 (2.6)
0.27, 0.54 90.2 (2.0) 74.1 (3.0) 78.6 (2.8)
>0.54 77.6 (2.8) 67.5 (3.2) 71.3 (3.1)
P = 0.004 P = 0.01 P = 0.005
uPA: urokinase-type plasminogen activator, p53: p53 protein, s.d.: standard
deviation, aprespecified percentiles.540 P Broët et al
British Journal of Cancer (1999) 80(3/4), 536–545 © Cancer Research Campaign 1999
0
3
0
5
0
8
0
1
0
0
u
P
A
D
i
s
e
a
s
e
-
s
p
e
c
i
f
i
c
 
s
u
r
v
i
v
a
l
 
(
%
)
0
.
1
3
0
.
1
3
,
 
0
.
2
4
0
.
2
4
,
 
0
.
3
9
0
.
3
4
,
 
0
.
7
2
0
.
7
2
0
2
4
6
0
1
2
0
9
6
0
3
0
5
0
8
0
1
0
0
u
P
A
0
.
1
3
0
.
1
3
,
 
0
.
2
4
0
.
2
4
,
 
0
.
3
9
0
.
3
4
,
 
0
.
7
2
0
.
7
2
0
2
4
6
0
1
2
0
9
6
D
i
s
e
a
s
e
-
f
r
e
e
 
i
n
t
e
r
v
a
l
 
(
%
)
0
3
0
5
0
8
0
1
0
0
u
P
A
0
.
1
3
0
.
1
3
,
 
0
.
2
4
0
.
2
4
,
 
0
.
3
9
0
.
3
4
,
 
0
.
7
2
0
.
7
2
0
2
4
6
0
1
2
0
9
6
D
i
s
t
a
n
t
 
r
e
c
u
r
r
e
n
c
e
-
f
r
e
e
 
i
n
t
e
r
v
a
l
 
(
%
)
T
i
m
e
 
(
m
o
n
t
h
s
)
T
i
m
e
 
(
m
o
n
t
h
s
)
T
i
m
e
 
(
m
o
n
t
h
s
)
F
i
g
u
r
e
 
1
D
i
s
e
a
s
e
-
s
p
e
c
i
f
i
c
,
 
d
i
s
e
a
s
e
-
f
r
e
e
 
a
n
d
 
d
i
s
t
a
n
t
 
r
e
c
u
r
r
e
n
c
e
-
f
r
e
e
 
s
u
r
v
i
v
a
l
 
c
u
r
v
e
s
 
a
c
c
o
r
d
i
n
g
 
t
o
 
u
P
A
 
q
u
a
n
t
i
l
e
sQuantitative biochemical assays of uPA and p53 in 1245 primary breast cancer patients 541
British Journal of Cancer (1999) 80(3/4), 536–545 © Cancer Research Campaign 1999
0
3
0
5
0
8
0
1
0
0
p
5
3
D
i
s
e
a
s
e
-
s
p
e
c
i
f
i
c
 
s
u
r
v
i
v
a
l
 
(
%
)
0
.
0
5
0
.
0
5
,
 
0
.
1
4
0
.
1
4
,
 
0
.
2
7
0
.
2
7
,
 
0
.
5
4
0
.
5
4
0
2
4
6
0
1
2
0
9
6
0
3
0
5
0
8
0
1
0
0
p
5
3
0
.
0
5
0
.
0
5
,
 
0
.
1
4
0
.
1
4
,
 
0
.
2
7
0
.
2
7
,
 
0
.
5
4
0
.
5
0
2
4
6
0
1
2
0
9
6
D
i
s
e
a
s
e
-
f
r
e
e
 
i
n
t
e
r
v
a
l
 
(
%
)
0
3
0
5
0
8
0
1
0
0
p
5
3
0
.
0
5
0
.
0
5
,
 
0
.
1
4
0
.
1
4
,
 
0
.
2
7
0
.
2
7
,
 
0
.
5
4
0
.
5
0
2
4
6
0
1
2
0
9
6
D
i
s
t
a
n
t
 
r
e
c
u
r
r
e
n
c
e
-
f
r
e
e
 
i
n
t
e
r
v
a
l
 
(
%
)
T
i
m
e
 
(
m
o
n
t
h
s
)
T
i
m
e
 
(
m
o
n
t
h
s
)
T
i
m
e
 
(
m
o
n
t
h
s
)
F
i
g
u
r
e
 
2
D
i
s
e
a
s
e
-
s
p
e
c
i
f
i
c
,
 
d
i
s
e
a
s
e
-
f
r
e
e
 
a
n
d
 
d
i
s
t
a
n
t
 
r
e
c
u
r
r
e
n
c
e
-
f
r
e
e
 
s
u
r
v
i
v
a
l
 
c
u
r
v
e
s
 
a
c
c
o
r
d
i
n
g
 
t
o
 
p
5
3
 
q
u
a
n
t
i
l
e
s542 P Broët et al
British Journal of Cancer (1999) 80(3/4), 536–545 © Cancer Research Campaign 1999
as a continuous variable. The risk of death, disease recurrence and
distant recurrence increased by 1.50, 1.45 and 1.39 times, respec-
tively, when log (uPA) increased by one unit. For instance, a
patient with a uPA value of 0.72 ng mg–1 protein (the 80th
percentile) was 1.5 times more likely to die than a patient with a
uPA value of 0.26 ng mg–1 of protein (above the 40th percentile).
The only parameter for which a significant time-varying effect was
observed was ER status (P < 0.001). No time-dependent effect was
observed for uPA, whatever the outcome. When testing interaction
terms in the model, the effect of uPA and p53 was of the same
magnitude in the different treatment groups (hormone therapy,
chemotherapy, radiotherapy).
Multivariate analysis – node-negative patients (Table 6)
Patients with high uPA levels, under 45 years old and with a histo-
logical grade higher than I had a shorter disease-free interval and
an increased risk of distant recurrences. Except for age, the same
factors were associated with an increased risk of disease-related
death. The risk of death, disease recurrence and distant recurrence
increased by 1.96, 1.63 and 1.85 times, respectively, when log
(uPA) increased by one unit. p53 had no significant influence on
any of the three outcomes.
Table 5 Multivariate analysis (overall population)
Variable e Disease-specific e Disease-free e Distant-recurrence-free
survivala intervala intervala
Axillary node 1 2 1
status (pN)
None 1 1 1
1–3 1.66 [1.14–2.42] 1.16 [0.83–1.62]d 1.31 [0.91–1.88]d
>3 3.69 [1.76–5.74] 2.29 [1.63–3.22] 2.69 [1.88–3.86]
uPA 2 1 2
(log) 1.50 [1.26–1.79] 1.45 [1.23–1.69] 1.39 [1.19–1.62]
Histological 3 3 4
grading (SBR)
I1 1 1
II 1.90 [0.91–4.01]d 2.22 [1.26–3.91] 2.10 [1.15–3.83]
III 2.55 [1.20–5.47] 2.88 [1.88–4.40]c 2.50 [1.03–5.30]c
ER 4 5 5
Positive 1 1 1
Negative 1.76 [1.26–2.45] 1.43 [1.09–1.88] 1.40 [1.05–1.87]
Pathological 5 4 3
tumour size (pT)
≤ 20 mm 1 1 1
> 20 mm 1.58 [1.06–2.35] 1.84 [1.34–2.55] 1.85 [1.30–2.62]
p53
(log) 1.14 [0.82–1.59]b 0.98 [0.90–1.06]b 1.14 [0.85–1.54]b
uPA: urokinase-type plasminogen activator as continuous variable (log transformed), p53: p53 protein as continuous variable
(log transformed). aRelative risk and confidence interval 95% (relative risk are referred to the best prognosis group)
bnon-significant, cnon-significant with the upper group, dnon-significant with the lower group, e: step entry in the Cox model.
Table 6 Multivariate analysis (node-negative patients)
Variable e Disease-specific e Disease-free e Distant-recurrence-free
survivala intervala intervala
uPA (log) 1 1 1
1.96 [1.42–2.71] 1.63 [1.31–2.02] 1.85 [1.41–2.42]
Histological 2 3 3
grading (SBR)
I1 11
II 2.67 [1.06–6.75] 2.78 [1.43–5.42] 2.67 [1.27–5.59]
III 2.91 [1.36–8.16]c 2.72 [1.20–5.30]c 2.57 [1.30–5.80]c
Age 2 2
≤ 45 years 1.21 [0.67–2.17]b 1.86 [1.24–2.79] 1.75 [1.10–2.77]
> 45 years 1 1 1
p53
(log) 0.94 [0.81–1.09]b 0.96 [0.85–1.07]b 0.98 [0.86–1.11]b
uPA: urokinase-type plasminogen activator as continuous variable (log transformed), p53: p53 protein as continuous variable
(log transformed). aRelative risk and confidence interval 95% (relative risk are referred to the best prognosis group)
bnon-significant, cnon-significant with the upper group, dnon-significant with the lower group, e: step entry in the Cox model.Quantitative biochemical assays of uPA and p53 in 1245 primary breast cancer patients 543
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DISCUSSION
In this study, uPA and p53 were detected with a reliable LIA
quantitative assay, which can easily be performed on cytosols
prepared for steroid receptor analysis. This biochemical method
has the advantage of being automated, reproducible, simple and
adaptable to routine clinical use.
This was a multicentre study with inherent advantages and
pitfalls. Among the advantages is the large number of patients,
meaning that valid conclusions can be drawn despite a heteroge-
neous population. The variations in uPA and p53 values from one
centre to another were probably not due to differences in the way
the assay was carried out. Indeed, as part of the quality control
process, identical specimens were assayed in several centres and
the results were not significantly different from one centre to
another. Moreover, an automatic method was used, minimizing
inter-laboratory variations. However, there were differences
among the centres in the storage of tumours or cytosols, and these
probably led to differences in uPA and, to a lesser degree, p53
distribution. Higher uPA values were observed in centres which
specifically prepared cytosols for this study. Differences could
also be ascribed to regional dissimilarities in patient selection. The
multivariate statistical analysis took this centre effect into account
and the results were adjusted for it.
Comparisons of the results of different published studies on the
prognostic value of uPA and p53 are difficult, mainly because
different cut-points were used (Table 7). UPA and p53 values and,
consequently, the cut-points, are highly dependent on sample
storage conditions, assay methodology, the population selected
and statistical methods. Regarding this latter point, continuous
variables are frequently analysed using the so-called ‘optimal
cutpoint’ approach that is known to overestimate the effect of
variables (Altman et al, 1994) and rule out comparisons between
studies. In this large series, with a view to later comparisons with
other studies, we chose to investigate the prognostic value of uPA
and p53 by using four prespecified percentiles based on the overall
population. This allowed us to analyse the relationship between
the markers and outcomes. The linear relationship in our final
model is in adequacy with the results of the univariate survival
analysis.
Published studies generally show a correlation between p53
protein accumulation or point mutations of the p53 gene and an
aggressive tumour phenotype (Veculescu and El-Deiry, 1996).
Immunohistochemistry is the most widely used method, with
different antibodies and different definitions of tumour positivity,
leading to different results regarding prognostic or predictive
value (Allred et al, 1993; MacGrogan et al, 1995). In contrast,
there have been only a few reports on p53 gene alteration in large
series of breast cancer (De Witte et al, 1996; Sjörgen et al, 1996;
Falette et al, 1998).
We measured p53 with a quantitative immunoluminometric
method (LIA) with antibodies 1801 and DO1, as described by
Borg et al (1995) and, later, De Witte et al (1996), Berns et al
(1997) and Peyrat et al (1998). The positive correlations we
observed between p53 levels and tumour grade and size are in
keeping with the literature. Like Borg et al (1995), De Witte et al
(1996), Berns et al (1997) and Peyrat et al (1998), we found that
p53 overexpression was associated with shorter distant recurrence-
free survival in univariate analysis. The influence of p53 remained
significant in the multivariate analyses done by Borg et al (1995)
and De Witte et al (1996), while, like Peyrat et al (1998), we found
that p53 was no longer significant in a multivariate analysis
including uPA and SBR grade. Other authors did not include histo-
logical grade or uPA levels in their multivariate studies, and the
strong correlation between high grade and p53 positivity may
partly explain why Cox analysis including the two parameters
reduces the influence of p53. The use of optimum cut-points
would also have considerably overestimated the effect of p53 at
the expense of other important variables, and this could explain
why p53, expressed as a quantitative variable, was not significant
in our multivariate analysis. Moreover, we found no interaction
between p53 and the type of treatment. As shown in Table 7, the
p53 median values in the LIA method are close from one study to
another, except for Borg et al (1995) who used cytosols which had
been frozen and thawed twice before LIA assay; however, the cut-
points and statistical methods used to determine them were quite
different as in immunohistochemical studies. The anti-p53 anti-
bodies used in LIA and immunohistochemistry (IHC) assays are
specific for denaturation-resistant epitopes of the NH2-terminus of
the protein, thus recognizing both mutant and wild-type proteins;
in addition, the wild-type protein can be more stable in the absence
of p53 gene alterations (Veculescu et al, 1996). Several investiga-
tors have found discrepancies between p53 protein expression and
mutation status, with large numbers of false-positive and false-
negative results (Elledge et al, 1994; Sjögren et al, 1996; Falette
et al, 1998); negative results cannot rule out mutations, and
Table 7 Different cut-off values in multivariate analysis for uPA and p53 assayed by using luminometric assay
Study n Median Cut-point % (+)a Statistical methodb
ng mg–1 ng mg–1
protein protein
uPA
Fernö et al, 1996 688 0.40 0.62 30% Minimum P-value of the log-rank
Bouchet et al, 1998 499 0.38 1.14 10% Minimum P-value of the log-rank
(with correction)
Peyrat et al, 1998 634 0.30 0.5 27.5% Optimum cutoff
p53
Borg et al, 1995 205 0.05 0.15 30% Minimum P-value of the log-rank
De Witte et al, 1996 142 0.40 2.5 28% Isotonic regression
Berns et al, 1998 1491 0.20 0.38 34% Isotonic regression
Peyrat et al, 1998 634 0.38 4 13.7% Optimum cutoff
n: Number included in the study. a% of patients uPA or p53 positive according to the chosen cutpoint, bStatistical methodology used for analysis.544 P Broët et al
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positive results must be confirmed by sequencing. De Witte et al
(1996), comparing LIA and single-strand conformation polymor-
phism, found a disagreement in 22% of the 142 cases analysed.
Finally, interpretation of p53 protein accumulation in a tumour is
difficult whatever the method (LIA or IHC), and prognostic data
obtained by gene sequencing are certainly more reliable. The value
of IHC and luminometric assays could be restricted to screening
for p53 mutations. Moreover, the contribution of a true quantita-
tive method appears limited in the case of p53, the main question
being the significance of p53 protein accumulation (Elledge,
1996).
Studies of many different human cancers, including breast
cancer, have shown that high levels of uPA correlate with poor
outcome. uPA was always assayed biochemically and appears to
be one of the strongest prognostic markers so far described in
breast cancer as informative as nodal status, in spite of differences
in extraction buffers, uPA standards and antibodies, and a lack of
uniform cut-points (Duffy, 1996). In this study we used hormone
receptor buffer, which yields lower uPA values than Triton X-100
buffer (Janicke et al, 1994a; Knoop et al, 1998). However, signifi-
cant prognostic value has also been observed with cytosols
prepared for hormone receptor assays (Foekens et al, 1992;
Bouchet et al, 1994, 1998; Jänicke et al, 1994a; Fernö et al, 1996;
Peyrat et al, 1998). Our technique has the advantage of being
automated. Bouchet (1998) recently showed a good concordance
between the results of the most widely used enzyme-linked
immunosorbent assay (ELISA) test for uPA (American
Diagnostica) and the LIA assay, although the two methods were
not interchangeable: indeed, lower uPA levels were obtained with
luminometry on cytosols prepared for hormone receptor assays. If
we compare our results to those of studies using the same assay
(Fernö et al, 1996; Peyrat et al, 1998), median uPA values were
close (Table 7). We confirm the negative correlation between uPA
levels and ER status, and the positive correlations between uPA
levels, histological grade and tumour size (Duffy, 1996). In our
study, the prognostic value of uPA was comparable to that of
lymph node involvement, and a high uPA level was still an inde-
pendent prognostic indicator in multivariate analysis, confirming
previous studies based on ELISA methods (Foekens et al, 1992;
Jänicke et al, 1993; Duffy, 1996; Bouchet et al, 1998) or LIA
(Fernö et al, 1996; Bouchet et al, 1998; Peyrat et al, 1998).
The search for additional markers in node-negative patients is a
major issue. In our analysis, after adjustment for other factors, uPA
was the main prognostic factor for the three outcomes in the multi-
variate analysis of this low-risk group, in agreement with previous
data based on ELISA methods (Foekens et al, 1992; Jänicke et al,
1993), LIA (Fernö et al, 1996; Peyrat et al, 1998) or both (Bouchet
et al, 1998). uPA is only part of the plasminogen activation system,
which includes complex interactions between uPA, its inhibitors
PAI-1 and PAI-2, and its receptor uPAR, in different cell compo-
nents. A study by Schmitt et al (1997) suggested that the estimated
hazards ratio for uPA could fall with time, contrary to PAI-1,
which remained stable, but the presented figures did not show
clearly a non-proportional hazards effect for uPA. We found no
time-related fall in the hazards ratio for uPA, whereas this effect
was highly significant for ER status, in accordance with Pichon
et al (1996). PAI-1 has also been found more predictive than uPA,
particularly in node-negative patients (Jänicke et al, 1993; Bouchet
et al, 1994; Foekens et al, 1994), but its pathophysiological role is
unclear, contrary to uPA (Andreasen et al, 1997). The importance
of uPA as a prognostic factor in breast cancer is underlined by its
role in metastasis, and by its value in node-negative patients, in
whom uPA is not redundant with proliferative markers, including
SBR grade. We found no interaction between uPA and treatment
modalities. However, it is important to take uPA into account in
randomized prospective trials as a new treatment stratification
parameter for node-negative patients. A question of special
interest is whether high uPA levels, which place node-negative
patients in a high-risk group, affect the response to therapy, and
this issue is currently being addressed in Jänicke’s clinical trial
(1994b).
In conclusion, this large multicentre study confirms the impor-
tance of uPA in predicting the outcome of node-negative breast
cancer patients, without using optimal cut-points and in spite of
differences among centres (taken into account in the multivariate
analyses). The predictive power of uPA in these conditions argues
for general use of this variable in clinical practice. In our series,
however, the quantitative assessment of p53 protein accumulation
added no prognostic information in the multivariate approach
including uPA and histological grade.
ACKNOWLEDGEMENTS
We thank all the pathologists and clinician teams of the different
centres who actively participated in the study. We are also grateful
for the expert technical assistance of the persons involved in the
luminometric assays of uPA and p53 in each centre. The help of
Sangtec in the uPA and p53 luminometric assays is gratefully
acknowledged.
REFERENCES
Akaike H (1974) A new look at the statistical model identification. IEEE
Transactions on Automatic Control 19: 716–723
Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne
CK and McGuire WL (1993) Association of p53 protein expression with tumor
cell proliferation rate and clinical outcome in node-negative breast cancer.
J Natl Cancer Inst 85: 200–206
Altman DG (1991) Categorising continuous variables. Br J Cancer 64: 975
Altman DG, Lausen B, Sauerbrei W and Schumacher M (1994) Dangers of using
‘optimal’ cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst
86: 829–835
Andreasen PA, Kioller L, Christensen L and Duffy MJ (1997) The urokinase-type
plasminogen activator system in cancer metastasis: a review. Int J Cancer 72:
1–22
Banks L, Matlashewski G and Crawford L (1986) Isolation of human p53 specific
monoclonal antibodies and their use in the studies of human p53 expression.
Eur J Biochem 159: 529–534
Berns EMJJ, De Witte HH, Klinj JGM, Willman K, Look MP, Meijer-van Gelder
ME, Benraad T and Foekens J (1997) Prognostic value of TP53 protein
accumulation in human primary breast cancer: an analysis by luminometric
immunoassay on 1491 tumor cytosols. Anticancer Res 17: 3003–3006
Bloom HJ and Richardson WW (1957) Histological grading and prognosis in breast
cancer. Br J Cancer 11: 359–377
Borg A, Lennersand J, Stenmark-Askmalm M, Fernö M, Brisfors A, Öhrvik A  Stål
O, Killander D, Lane D and Brundell J (1995) Prognostic significance of p53
overexpression in primary breast cancer; a novel luminometric immunoassay
applicable on steroid receptor cytosols. Br J Cancer 71: 1013–1017
Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A and Oglobine J (1994)
Prognostic value of urokinase activator and plasminogen activator inhibitors
PAI-1 and PAI-2 in breast carcinoma. Br J Cancer 69: 398–405
Bouchet C, Spyratos F, Hacène K, Durcos L, Bécette V and Oglobine J (1998)
Prognostic value of urokinase activator in primary breast carcinoma:
comparison of two immunoassay methods. Br J Cancer 77: 1495–1501
Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc B
34: 187–202
De Witte HH, Foekens JA, Lennerstrand J, Smid M, Look MP, Klijn GM, Benraad
TJ and Berns MJJ (1996) Prognostic significance of tp53 accumulation inQuantitative biochemical assays of uPA and p53 in 1245 primary breast cancer patients 545
British Journal of Cancer (1999) 80(3/4), 536–545 © Cancer Research Campaign 1999
human primary breast cancer: comparison between a rapid quantitative
immunoassay and SSCP analysis. Int J Cancer 69: 125–130
Duffy MJ (1996) Proteases as prognostic markers in cancer. Clin Cancer Res 2:
613–618
Elledge RM (1996) Assessing p53 status in breast cancer prognosis; where should
you put the thermometer if you think your p53 is sick? J Natl Cancer Inst 88:
141–142
Elledge RM, Clark GM, Fuqua SAW and Yu YY (1994) Allred C: p53 protein
accumulation detected by five different antibodies: relationship to prognosis
and heat shock protein 70 in breast cancer. Cancer Res 54: 3752–3757
EORTC (European Organization for Research and Treatment of Cancer) (1980)
Breast cancer cooperative group. Revision of the standards for the assessment
of hormone receptors in human breast cancer. Eur J Cancer 16: 1513–1515
Falette N, Paperin Mp, Treilleux I, Gratadour AC, Peloux N, Mignote H, Tooke N,
Lofman E, Iganas M, Brémond A, Ozturk M and Puisieux A (1998) Prognostic
value of p53 gene mutations in a large series of node-negative breast cancer
patients. Cancer Res 58: 1451–1456
Fernö M, Bendahl, P.O, Borg A, Brundell J, Hirschberg L, Olsson H and Killander D
(1996) Urokinase plasminogen activator, a strong independent prognostic
factor in breast cancer, analysed in steroid receptor cytosols with luminometric
immunoassay. Eur J Cancer 5: 793–801
Figueroa JA, Yee D and McGuire WL (1993) Prognostic indicators in early breast
cancer. Am J Med Sci 305: 176–182
Foekens JA, Schmitt M, Van Putten WLJ, Peters HA, Bontenbal M, Jänicke F and
Klijn JGM (1992) Prognostic value of urokinase-type plasminogen activator in
671 primary breast cancer. Cancer Res 52: 6101–6105
Foekens JA, Schmitt M, Van Putten WLJ, Peters HA, Kramer MD, Jäunicke F and
Klijn JGM (1994) Plasminogen activator inhibitor-1 and prognosis in primary
breast cancer. J Clin Oncol 12: 1648–1658
Gottlieb TM and Oren M (1996) p53 in growth control and neoplasia. Biochem
Biophys Acta 1287, 77–102
Jänicke F, Schmitt M, Pache L, Harbeck N, Höfler H and Graeff H (1993) Urokinase
(uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in
node-negative breast cancer. Breast Cancer Res Treat 24: 195–208
Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A and Graeff H
(1994a) Both the cytosols and detergent extracts of breast cancer tissues are
suited to evaluate the prognostic impact of the urokinase-type plasminogen
activator and its inhibitor plasminogen activator inhibitor-type 1. Cancer Res
54: 2527–2530
Jänicke F, Thomssen C, Pache M, Schmitt M and Graeff H (1994b) Urokinase (uPA)
and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node-
negative breast cancer patients. In Prospects in Diagnosis and Treatment of
Breast Cancer, Schmitt M, Graeff H and Kendermann G (eds) pp. 207–218.
Excerpta Medica: Amsterdam
Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete
observations. J Am Stat Assoc 53: 457–481
Knoop A, Andreasen PA, Andreasen JA, Hansen S, Laenkholm AV, Simonsen ACW,
Andersen J, Overgaard J and Rose C (1998) Prognostic significance of
urokinase-type plasminogen activator and type plasminogen activator
inhibitor-1 in primary breast cancer. Br J Cancer 77: 932–940
MacGrogan G, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A and
Coindre JM (1995) Prognostic value of p53 in breast invasive ductal
carcinoma: an immunohistochemical study of 942 cases. Breast Cancer Res
Treat 36: 71–81
Mantel N (1966) Evaluation of survival data and two rank order statistics arising in
its consideration. Cancer Chemother Res 50: 163–170
Peyrat JP, Vanlemmens L, Fournier J, Huet G, Révillon F and Bonneterre J (1998)
Prognostic value of p53 and urokinase-type plasminogen activator in node
negative human breats cancers. Clin Cancer Res 4: 189–196
Pichon MF, Broët P, Magdelenat H, Delarue JC, Spyratos F, Basuyau JP, Saez S,
Rallet A, Courrière R, Millon R and Asselain B (1996) Prognostic value of
steroid receptors after long-term follow-up of 2257 operable breast cancer.
Br J Cancer 73: 1545–1552
Porter-Jordan K and Lippman ME (1994) Overview of the biologic markers of
breast cancer. Hematol Oncol Clin North Am 8: 73–100
Scarff RW and Torloni H (1968) Histological Typing of Breast Tumors, pp. 13–20.
World Health Organization: Geneva 13–20
Schmitt M, Thomssen C, Ulm K, Selderer A, Harbeck N, Höfler H, Jänicke F and
Graeff H (1997) Time-varying prognostic impact of tumour biological factors
urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast
cancer. Br J Cancer 76: 306–311
Sjörgren S, Iganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L and Bergh J
(1996) The p53 gene in breast cancer: prognostic value of complementary
DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88:
173–182
S-Plus Version 3.2 Guide to Statistics (1993) Statistical Sciences: Seattle, WA
Therneau TM, Grambsch PM and Fleming TR (1990) Martingale-based residuals for
survival models. Biometrika 77: 147–160
Thor AD and Yandell DW (1993) Prognostic significance of p53 overexpression in
node-negative breast carcinomas: preliminary results support cautious
optimism. J Natl Cancer Inst 85: 176–177
UICC (Union Internationale Contre le Cancer) (1988) TNM Classification des
Tumeurs Malignes, Springer-Verlag: Paris pp. 99–106
Velculescu VE and El-Deiry WS (1996) Biological and clinical importance of the
p53 tumor suppressor gene. Clin Chem 42: 858–868
Vojtesek B, Bártek J, Migdley CA and Lane DP (1992) An immunochemical
analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies
and epitope mapping using recombinant p53. J Immuno Methods 151: 237–244